Loading clinical trials...
Loading clinical trials...
Validation of the Use of the "ELN 2022" Risk Stratification System in HLA MENAFC Patients Newly Diagnosed With Acute Myeloid Leukemia
Conditions
Interventions
Middle Eastern or North Coast of Africa patients with newly AML
Locations
1
France
CHU NICE
Nice, Alpes Maritimes, France
Start Date
August 1, 2024
Primary Completion Date
August 1, 2024
Completion Date
January 1, 2025
Last Updated
July 22, 2024
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06537726
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions